Dr. Sirott's research primarily targets advanced esophageal cancer, particularly a type called epidermoid carcinoma, which is known for having a better response to certain treatments. He studies the effectiveness of drug combinations, such as interferon alpha-2A, 5-fluorouracil, and cisplatin, in fighting this aggressive cancer. Additionally, he explores safety and dosage parameters for the chemotherapy drug topotecan, aiming to refine treatment options for patients with various advanced solid tumors. This work is crucial for improving survival rates and quality of life for cancer patients.
Key findings
In a study involving 27 patients with advanced esophageal carcinoma, 50% experienced significant improvement, while 8% achieved complete remission.
Epidermoid carcinoma patients had a response rate of 73% to the three-drug combination treatment compared to a 33% response rate in adenocarcinoma patients.
In a trial of topotecan, the highest safe dose established was 1.75 mg/m² for untreated patients and 1.50 mg/m² for those who had received prior treatments.
Frequently asked questions
Does Dr. Sirott study esophageal cancer?
Yes, Dr. Sirott focuses on advanced esophageal cancer, particularly treatments for epidermoid carcinoma.
What treatments has Dr. Sirott researched?
He has researched a combination of interferon alpha-2A, 5-fluorouracil, and cisplatin, as well as the chemotherapy drug topotecan.
Are his findings relevant for patients with advanced solid tumors?
Yes, his research on topotecan provides important safety guidelines and dosage recommendations for patients with advanced solid tumors.
Publications in plain English
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
1995
Cancer
Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y +2 more
Plain English This study explored a combination treatment of three drugs—interferon alpha-2A, 5-fluorouracil, and cisplatin—on patients with advanced esophageal cancer that couldn’t be surgically removed. Out of 27 patients treated, 50% showed significant improvement in their condition, with 8% achieving complete remission. The results indicate that this treatment may work particularly well for one type of esophageal cancer, known as epidermoid carcinoma, which had a response rate of 73% compared to 33% for adenocarcinoma.
Who this helps: This research benefits patients with advanced esophageal cancer, especially those with epidermoid carcinoma.
Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
1993
Journal of the National Cancer Institute
Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D +5 more
Plain English This study looked at the cancer drug topotecan, given daily for five days to patients with advanced solid tumors. Researchers found that the highest safe dose was 1.75 mg/m² for patients who hadn’t undergone prior treatment and 1.50 mg/m² for those who had been treated before. The biggest side effect was low white blood cell counts, and they concluded that topotecan can be given safely on a 21-day cycle, although using another drug to boost its effects didn’t allow for higher doses due to additional side effects.
Who this helps: This helps cancer patients and doctors by providing safe dosage guidelines for using topotecan in treatment.